Traveler’s Diarrhea Market

Market Overview:

The 7 major traveler’s diarrhea markets reached a value of USD 1,314.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,311.3 Million by 2035, exhibiting a growth rate (CAGR) of 5.26% during 2025-2035.

The traveler’s diarrhea market has been comprehensively analyzed in IMARC's new report titled "Traveler’s Diarrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Traveler's diarrhea is a type of unpleasant gastrointestinal infection that occurs upon the consumption of contaminated food or water during travel. It is most caused by the E. coli bacteria, but can also be developed by other organisms, like viruses and parasites. The symptoms of this condition usually include abdominal cramps and pain, nausea, vomiting, sudden onset of the passage of more than two watery stools a day, bloating, loss of appetite, urgent and frequent bowel movements, etc. In severe cases, individuals suffering from the ailment may also experience dehydration, dry mouth, fatigue, weakness, blood in the stool, headaches, dizziness, and electrolyte imbalances. The diagnosis of this illness is mainly based on the identification of the patient's indications and comprehensive travel history. Several medical exams and laboratory tests are performed to check a person's overall health and rule out any further diseases that could be causing the symptoms. The healthcare provider may also conduct stool cultures and polymerase chain reaction (PCR) tests to validate the diagnosis among patients.

The increasing cases of viral, bacterial, and parasitic infections on account of poor public hygiene, resulting in contaminated food or water, are primarily driving the traveler's diarrhea market. In addition to this, the rising incidences of several associated risk factors, such as young adult tourists, unhealthy dietary choices, a weakened immune system, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antimotility agents, involving loperamide and diphenoxylate, for managing disease symptoms by controlling gastrointestinal muscle spasms and reducing the frequency of bowel movements is acting as another significant growth-inducing factor. Additionally, the growing application of lifestyle modifications, which include the consumption of a BRAT (bananas, rice, applesauce, and toast) diet that helps in easing stomach distress as well as preventing dehydration in patients, is further augmenting the market growth. Apart from this, the emerging popularity of oral hydration formulas, since they can optimize fluid absorption in the intestines, thereby quickly replenishing electrolytes in the body, is expected to drive the traveler's diarrhea market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the traveler’s diarrhea market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for traveler’s diarrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the traveler’s diarrhea market in any manner.

Key Highlights:

• Traveler's diarrhea is a common disease among those who go to resource-limited destinations abroad.
• It is estimated to affect about 40-60 percent of travelers and is the most common travel-related ailment.
• Among tourists from wealthy countries who visit developing countries, >60% are susceptible to traveler' diarrhea, amounting for 40,000 travelers daily or more than 15 million annually.
• The incidence and causal agent differ by destination, with Sub-Saharan Africa having the greatest reported incidence.
• Other areas with a high incidence include Latin America, the Middle East, and South Asia.

Drugs:

AEMCOLO is a rifamycin-based antibiotic used to treat travelers' diarrhea triggered by noninvasive strains of Escherichia coli in adults. AEMCOLO should be taken twice daily (morning and evening) for three days at a dose of 388 mg (two tablets). It is a yellow-brown, ellipsoidal, film-coated, delayed-release tablet that contains 194 mg of rifamycin.

Travelan (IMM-124E) contains enterotoxigenic Escherichia coli (ETEC) -specific antibodies that can protect against the clinical symptoms of traveler's diarrhea. Immuron is pursuing an FDA clinical pathway with Travelan to allow the product to marketed in the US as a drug to reduce the risk of contracting traveler's diarrhea.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the traveler’s diarrhea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the traveler’s diarrhea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current traveler’s diarrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the traveler’s diarrhea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the traveler’s diarrhea market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the traveler’s diarrhea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of traveler’s diarrhea across the seven major markets?
• What is the number of incident cases (2019-2035) of traveler’s diarrhea by age across the seven major markets?
• What is the number of incident cases (2019-2035) of traveler’s diarrhea by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with traveler’s diarrhea across the seven major markets?
• What is the size of the traveler’s diarrhea patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of traveler’s diarrhea?
• What will be the growth rate of patients across the seven major markets?
   

Traveler’s Diarrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for traveler’s diarrhea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the traveler’s diarrhea market?
• What are the key regulatory events related to the traveler’s diarrhea market?
• What is the structure of clinical trial landscape by status related to the traveler’s diarrhea market?
• What is the structure of clinical trial landscape by phase related to the traveler’s diarrhea market?
• What is the structure of clinical trial landscape by route of administration related to the traveler’s diarrhea market?